(Alliance News) - Creo Medical Group PLC on Monday said the first upper gastrointestinal tract using the Speedboat Inject procedure has been completed in Europe since its clearance last week.
Creo Medical, a Chepstow, Wales-based medical device company focused on surgical endoscopy, said that Adolfo Parra-Blanco from Nottingham Hospital NHS Trust became the first doctor to make clinical use of the procedure.
Speedboat Inject is a medical device using radio frequency and microwave energy to cut tissue, and is used in endoscopic procedures to remove cancerous lesions from the gastrointestinal system.
"What's clear to me is how well suited the Speedboat Inject device is for these types of procedures, and I foresee it dramatically increasing the number of patients able to benefit from this advanced energy, not only here in Nottingham but at healthcare settings elsewhere across Europe," said Parra-Blanco.
This successful procedure followed the announcement last Monday that Speedboat Inject had been cleared for use in Europe, with the company noting that it had a "healthy pipeline" of clinicians ready to use the device across Europe.
The procedure saw a 7 centimetre by 5 centimetre cancerous lesion in the stomach removed in one piece in little under two hours. Creo Medical said the results of the procedure were "excellent" and the patient left hospital shortly after.
The company said a second doctor has been trained to use Speedboat Inject for this procedure at Nottingham.
Courses at Nottingham University Hospital NHS Trust focussing on demonstrating Speedboat Inject on the upper gastrointestinal endoscopic submucosal system are set to take place both next week and in August at Queens Medical Centre, Nottingham.
The company said it will continue to work with Nottingham University Hospital NHS Trust to support "training, mentoring and adoption" of Speedboat Inject in the coming months.
"To have the first case completed at such a well-respected and prestigious endoscopic centre, renowned for its upper gastrointestinal services, so soon after clearance demonstrates both the appetite for the device to be used in the upper gastrointestinal tract in Europe and the ability for clinicians to quickly get optimal results once they are familiar with the advanced energy," said Chief Executive Officer Craig Gulliford.
Shares in Creo Medical were up 5.7% at 35.58 pence in London on Monday morning.
By Will Neill, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved
Creo Medical (CREO)